Exosomal nucleic acids (exoNAs) from NSCLC patient plasma for common BRAF, KRAS, and EGFR mutations showed higher sensitivity for assessing clinical outcomes as compared to plasma ctDNA [234]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.